I-Mab
I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment o… Read more
I-Mab (IMAB) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.007x
Based on the latest financial reports, I-Mab (IMAB) has a cash flow conversion efficiency ratio of 0.007x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.84 Million) by net assets ($258.92 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
I-Mab - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how I-Mab's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
I-Mab Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of I-Mab ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang Dehong Automotive
SHG:603701
|
-0.014x |
|
Nanjing Quanxin Cable Technology Co Ltd
SHE:300447
|
0.031x |
|
Shanghai QiFan Cable Co Ltd
SHG:605222
|
-0.047x |
|
Sichuan Shengda Forestry Industry Co Ltd
SHE:002259
|
0.164x |
|
Tianjin Keyvia Electric Co Ltd
SHE:300407
|
0.051x |
|
Nanjing Chemical Fibre Co Ltd
SHG:600889
|
-0.100x |
|
Tus-Sound Environmental Resources Co Ltd
SHE:000826
|
0.045x |
|
Schoeller-Bleckmann Oilfield Equipment Aktiengesellschaft
PINK:SBOEF
|
0.065x |
Annual Cash Flow Conversion Efficiency for I-Mab (2017–2024)
The table below shows the annual cash flow conversion efficiency of I-Mab from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $201.16 Million | $-52.67 Million | -0.262x | +65.53% |
| 2023-12-31 | $1.72 Billion | $-1.30 Billion | -0.760x | -107.18% |
| 2022-12-31 | $3.01 Billion | $-1.10 Billion | -0.367x | -72.83% |
| 2021-12-31 | $4.59 Billion | $-973.09 Million | -0.212x | -375.29% |
| 2020-12-31 | $5.63 Billion | $433.56 Million | 0.077x | -81.94% |
| 2019-12-31 | $-2.03 Billion | $-867.98 Million | 0.427x | +45.15% |
| 2018-12-31 | $-955.10 Million | $-280.70 Million | 0.294x | -65.06% |
| 2017-12-31 | $-299.80 Million | $-252.16 Million | 0.841x | -- |